Novo Nordisk Dividends and Buybacks

Dividend criteria checks 4/6

Novo Nordisk is a dividend paying company with a current yield of 2.29% that is well covered by earnings.

Key information

2.3%

Dividend yield

0.8%

Buyback Yield

Total Shareholder Yield3.1%
Future Dividend Yield3.4%
Dividend Growth12.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ratio48%

Recent dividend and buyback updates

Recent updates

Novo Nordisk: The Time To Buy Has Come

Jun 10

Novo Nordisk: Examining Tariff And Pricing Risks

Apr 26

Novo Nordisk: A Price Too Low To Ignore

Apr 18

Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors

Mar 30

Novo Nordisk: CagriSema Disappoints Again

Mar 10

Why Novo Nordisk Is A Strong Buy Despite Market Concerns

Feb 20

Novo Nordisk: Dips Like These Come Once Every Few Years

Feb 13
author-image

Novo Nordisk aims for a promising future with a fair value of 101.75

Revenue growth is expected to be driven by continued demand for GLP-1 drugs, especially Ozempic and Wegovy.

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Feb 05

Novo Nordisk: Excellent Opportunity To Buy The Dip

Jan 15

Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More Potential

Jan 06

Novo Nordisk Stock: A Rare Buying Opportunity

Dec 20

Novo Nordisk: Just The Right Price (Rating Upgrade)

Dec 11

Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?

Nov 25

Novo Nordisk: A GLP-1 Leader Faces Increasing Competition

Nov 06

Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued

Oct 21

Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy

Sep 18

Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now

Sep 10

Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation

Aug 18

Novo Nordisk: Growth Only Limited By Manufacturing Capacity

Aug 07

Novo Nordisk: Better Buying Opportunities Ahead

Jul 26

Novo Nordisk: Buy On Dips

Jul 04

Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy

Jun 26

Novo Nordisk: Leading The Fight Against Diabetes And Obesity

Jun 18

Novo Nordisk: Considerable Growth Beyond Ozempic

May 27

The FTC Cracks Down On Novo Nordisk's Ozempic

May 03

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

Apr 26

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: NVO's dividend payments have been volatile in the past 10 years.

Growing Dividend: NVO's dividend payments have increased over the past 10 years.


Dividend Yield vs Market

Novo Nordisk Dividend Yield vs Market
How does NVO dividend yield compare to the market?
SegmentDividend Yield
Company (NVO)2.3%
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast (NVO) (up to 3 years)3.4%

Notable Dividend: NVO's dividend (2.29%) is higher than the bottom 25% of dividend payers in the US market (1.58%).

High Dividend: NVO's dividend (2.29%) is low compared to the top 25% of dividend payers in the US market (4.74%).


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (48.5%), NVO's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonable cash payout ratio (68.1%), NVO's dividend payments are covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/16 23:24
End of Day Share Price 2025/06/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research